Details
Category: Volume 08 Issue 02 February 2020
Hits: 1013

Title: Comparative study of Dyslipidemia in Diabetic patients with Diabetic Nephropathy and Diabetic patients without Nephropathy

Authors: Dr Sunil Kumar, Dr Kaushal Kishore

 DOI: https://dx.doi.org/10.18535/jmscr/v8i2.66

Abstract

Dyslipidemia, is considered as an important risk factor for cardiovascular disease which is frequently complicated with diabetic nephropathy. Management of dyslipidemia in diabetic nephropathy is an extremely important factor because patients with diabetic nephropathy are at a high risk for cardiovascular disease-associated death.

Methods: The present study was conducted to explore the lipid abnormalities in diabetic patients with nephropathy in comparison with diabetic patients without nephropathy. This cross sectional study was conducted in the Department of General Medicine, OPD, & IPD of Patna Medical College & Hospital. This study included total 60 patients divided in two groups: diabetic patients with nephropathy group and diabetic patients without nephropathy group. Available data between two groups were analysed.

Results: In our study the commonest age group was 51-60 years in both groups. The mean age of patients in nephropathy and without nephropathy group was 51.96±8.81 and 51.466±7.62 years respectively. We observed no significant difference for age group between two groups. While comparing the mean fasting and postprandial blood glucose level and HbA1c level between two group nephropathy groups showed significantly higher level compared to without nephropathy group. The percentage of subjects with dyslipidemia was significantly higher in nephropathy group in this study.

Conclusion: Dyslipidemia is an important therapeutic target in the management of diabetes. Furthermore, diabetic nephropathy accelerates abnormal lipoprotein metabolism, which causes the progression of DN as well as cardiovascular disease.

References

  1. Durrington PN. Hyperlipidaemia: diagnosis and management. London: Hodder Arnold; 2007. 
  2. Emerging Risk Factors Collaboration. Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222.
  3. Rutledge JC, Ng KF, Aung HH, Wilson DW. Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol. 2010;6(6):361–70.
  4. Hirano T. Abnormal lipoprotein metabolism in diabetic nephropathy. Clin Exp Nephrol. 2014;18(2):206–9..
  5. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73(4):327–39.
  6. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
  7. Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, et al.Epidemiology and risk factors of chronic kidney disease in India – Results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol 2013;14:114.
  8. Haffner S, M, Lehto S, Ronnemaa T, Pyoratak, Laukso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
  9. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia: a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994;45:S125-31.
  10. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL; DCCT/EDIC Research Group. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 2003;64:817-28.
  11. Suchitra MM, Sheshu Kumar M, Bitla AR, Madhusudhana Rao A, Alok S. Atherogenic dyslipidemia in diabetic nephropathy: lipoprotein (a), lipid ratios and atherogenic index. Int J Res Med Sci 2013;1:455-9.
  12. Jisieike-Onuigbo NN, Unuigbe EI, Kalu OA, Oguejiofor CO, Onuigbo PC. Prevalence of dyslipidemia among adult diabetic patients with overt diabetic nephropathy in Anambra state south-east Nigeria. Niger J Clin Pract 2011;14:171-5.
  13. Jacobs DR Jr. Plasma lipid distributions in selected North American populations: The lipid research clinic program prevalence study. Lipid Research clinics Program Epidemiologic Committee. Circulation 1970;60:427-39.
  14. Agaba IE, Anteyi EA, Puepet FH, Omudu PA, Idoko JA. The clinical pattern of diabetic nephropathy in Type II diabetes mellitus in North Central Nigeria. J Med Tropics 2002;4:10.
  15. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 1998;13:2833-41.
  16. Abdul-Ramman AN, Olufunsho F. Hyperlipidemia among Saudi diabetic patients-pattern and clinical characteristics. Ann Saudi Med 1995;15:240-3.
  17. Shoji T, Emoto M, Kawagishi T, Kimoto E, Yamada A, Tabata T, Ishimura E, Inaba M, Okuno Y, Nishizawa Y. Atherogenic lipoprotein changes in diabetic nephropathy. Atherosclerosis 2001. 156(2): 425-433.
  18. Yang X, So WY, Ma R, Ko G, Kong A, Lam C, Ho CS, Cockram C, Chow CC, Tong P, et al. Effects of albuminuria and renal dysfunction on development of dyslipidaemia in type 2 diabetes - the Hong Kong Diabetes Registry. Nephrol Dial Transplant 2008. 23(9):2834-2840.
  19. Yamamoto T, So WY, Ma R, Ko G, Kong A, Lam C, Ho CS, Cockram C, Chow CC, Tong P, et al. Significant increase of apolipoprotein B48 levels by a standard test meal in type 2 diabetic patients with nephropathy. J Atheroscler Thromb 2008. 15(4):199-205.

Corresponding Author

Dr Kaushal Kishore

Professor, Department of Medicine, Patna Medical College & Hospital